References
- Weidinger S, Beck LA, Bieber T, et al. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1. doi:10.1038/s41572-018-0001-z.
- Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov. 2022;21(1):21–3. doi:10.1038/s41573-021-00266-6.
- Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (measure up 1 and measure up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):2151–2168. doi:10.1016/S0140-6736(21)00588-2.
- Simpson EL, Papp KA, Blauvelt A, et al. Efficacy and safety of upadacitinib in patients with moderate to severe atopic dermatitis: analysis of follow-up data from the measure up 1 and measure up 2 randomized clinical trials. JAMA Dermatol. 2022;158(4):404–413. doi:10.1001/jamadermatol.2022.0029.
- Guttman-Yassky E, Beck LA, Anderson JK, et al. Upadacitinib treatment withdrawal and retreatment in patientswith moderate-to-severe atopic dermatitis from a phase 2b, randomized, controlled trial. Poster Presented at 2019 American Academy of Dermatology Annual Meeting; p. 1–5. 2019 Mar.
- Guttman-Yassky E, Thaçi D, Pangan AL, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;145(3):877–884. doi:10.1016/j.jaci.2019.11.025.
- Chiricozzi A, Gori N, Narcisi A, et al. Effectiveness and safety of upadacitinib in the treatment of Moderate-Severe atopic dermatitis: a multicentric, prospective, Real-World, cohort study. Drugs R D. 2022;22(3):245–252. doi:10.1007/s40268-022-00396-1.
- Boesjes CM, Van der Gang LF, Zuithoff NPA, et al. Effectiveness of upadacitinib in patients with atopic dermatitis including those with inadequate response to dupilumab and/or baricitinib: results from the BioDay registry. Acta Derm Venereol. 2023;103:adv00872. doi:10.2340/actadv.v103.5243.